James M. Holaska

This study shows reduced emerin expression correlates with gastric cancer progression and nuclear remodeling, similar to findings in breast cancer.

This study develops emerin mRNA lipid nanoparticles (EMD-LNPs) to restore emerin protein expression in emerin-null myogenic progenitors, improving differentiation and showing low toxicity.

The paper examines emerin expression in breast cancer subtypes and finds it is reduced in aggressive subtypes, correlating with advanced stage, higher proliferation, and receptor-negative status.

This study shows emerin deficiency in breast cancer cells leads to smaller, misshapen nuclei and increased metastasis, with emerin expression inversely correlating with cancer invasiveness in patient samples.